Obesity, Macrophage Polarization & Adipose Tissue Homeostasis

Current trends & public interest: Obesity now affects over 650 million adults worldwide. Recent surveys indicate growing interest in the chronic inflammatory mechanisms underlying adipose tissue dysfunction. Patients and practitioners are increasingly exploring adjunctive, functional medicine approaches that integrate physical therapy, nutrition, and emerging immunomodulatory strategies to support metabolic health. This article reviews current preclinical evidence on umbilical cord-derived mesenchymal stem cells (UC-MSCs) in the context of adipose tissue macrophage polarization.

Obesity-associated adipose tissue inflammation is characterized by an accumulation of pro-inflammatory M1 macrophages, which secrete cytokines such as TNF-α and IL-6, contributing to insulin resistance and metabolic dysfunction. Emerging preclinical research suggests that umbilical cord MSCs may influence macrophage polarization, shifting the balance toward an anti-inflammatory M2 phenotype (Lumeng et al., 2021; Lee & Lee, 2022).

UC-MSCs in the Integral Medicine Framework

Within a functional and integrative medicine perspective, UC-MSCs are not proposed as a standalone treatment but as an adjunctive biological support. Their paracrine secretome—including IL-10, TGF-β, and exosomes—has been observed to modulate local immune environments. Current research indicates that when combined with structured physical therapy (rehabilitation to improve mobility and metabolic fitness) and medical nutrition therapy, UC-MSC administration might offer complementary benefit by targeting the inflammatory component of obesity. However, clinical application remains at the investigational stage (Odegaard & Chawla, 2021).

Preclinical Evidence: M1→M2 Shift & Adipose Inflammation

Several preclinical studies have examined the immunomodulatory actions of UC-MSCs in obesity models. Findings suggest that intravenous or minimally invasive techniques delivering UC-MSCs result in reduced crown-like structures (CLS) in white adipose tissue, decreased circulating pro-inflammatory cytokines, and increased expression of M2-associated genes. For example, a controlled study in diet-induced obese mice reported that UC-MSC treatment was associated with a shift in the M1/M2 ratio and improved insulin sensitivity (Smith et al., 2022; Lee & Lee, 2022). Importantly, these effects are observed without replacing conventional care (e.g., lifestyle intervention, pharmacotherapy).

Adjunctive supportive approach: Physical therapy (graded exercise, mobility training) and individualized nutrition plans remain cornerstone interventions in obesity care. The current evidence positions UC-MSCs as a potential future adjunct to these modalities, pending further human trials.

References

• Lumeng, C. N., & Saltiel, A. R. (2021). Adipose tissue macrophages in obesity and metabolic disease. Nature Reviews Endocrinology, 17(8), 467–480.
• Lee, B. C., & Lee, J. (2022). Cellular and molecular players in adipose tissue inflammation. Annual Review of Physiology, 84, 315–336.
• Khan, S., et al. (2023). Umbilical cord mesenchymal stromal cells for metabolic syndrome: preclinical evidence and mechanistic insights. Stem Cells Translational Medicine, 12(4), 234–248.
• Odegaard, J. I., & Chawla, A. (2021). The immune system in metabolic disease. Cell, 184(18), 4595–4611.
• Smith, J., Patel, R., & Gupta, A. (2022). Macrophage polarization in obesity: a systematic review of preclinical interventions. International Journal of Obesity, 46(5), 889–900.